Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A. Piha-Paul SA, et al. Among authors: benhadji ka. Invest New Drugs. 2021 Oct;39(5):1324-1334. doi: 10.1007/s10637-021-01104-7. Epub 2021 Mar 27. Invest New Drugs. 2021. PMID: 33774767 Free PMC article. Clinical Trial.
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E. Azaro A, et al. Among authors: benhadji ka. Invest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24. Invest New Drugs. 2015. PMID: 25902900 Clinical Trial.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E. Faivre SJ, et al. Among authors: benhadji ka. Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16. Invest New Drugs. 2015. PMID: 26377590 Clinical Trial.
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC. Pant S, et al. Among authors: benhadji ka. Eur J Cancer. 2016 Mar;56:1-9. doi: 10.1016/j.ejca.2015.11.021. Epub 2016 Jan 19. Eur J Cancer. 2016. PMID: 26798966 Free article. Clinical Trial.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Ikeda M, Morimoto M, Tajimi M, Inoue K, Benhadji KA, Lahn MMF, Sakai D. Ikeda M, et al. Among authors: benhadji ka. Invest New Drugs. 2019 Feb;37(1):118-126. doi: 10.1007/s10637-018-0636-3. Epub 2018 Jul 11. Invest New Drugs. 2019. PMID: 29995286 Free PMC article. Clinical Trial.
70 results